Pharmacotherapy for methamphetamine dependence: A review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions

Annals of Clinical Psychiatry

Volumn 20, Issue 3, 2008, Pages 145-155

  Rose, Mark E ^a,c   Grant, Jon E ^b  

^a North Central Medical Communications Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE   (United States)

Author keywords

Abstinence syndrome; Methamphetamine dependence; Neurotoxicity; Pathophysiology; Pharmacotherapy; Treatment

Indexed keywords

AMFEBUTAMONE; BACLOFEN; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; METHAMPHETAMINE; MIRTAZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VIGABATRIN;

BECK DEPRESSION INVENTORY; CLINICAL FEATURE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG USE; HUMAN; MEDICAL LITERATURE; METHAMPHETAMINE DEPENDENCE; NEUROTOXICITY; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT CARE; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REINFORCEMENT; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

AMPHETAMINE-RELATED DISORDERS; AMYGDALA; CENTRAL NERVOUS SYSTEM STIMULANTS; CHRONIC DISEASE; HUMANS; METHAMPHETAMINE; NEUROTRANSMITTER AGENTS; NUCLEUS ACCUMBENS; RECURRENCE;

EID: 47549110206     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230802177656     Document Type: Review

References (77)

1. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev. 2001;36:1-22.
2. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol. 2005;75:406-433.
3. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: A literature review. Harv Rev Psychiatry. 2005;13:141-154.
4. Logan BK. Amphetamines: An update on forensic issues. J Anal Toxicol. 2001;25:400-404.
5. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006;26:1148-1156.
6. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002;21:21-34.
7. Cadet JL, Jayanthi S, Deng X. Speed kills: Cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 2003;17:1775-1788,
8. Hanson GR, Sandoval V, Riddle E, Fleckenstein AE. Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications. Ann NY Acad Sci. 2004;1025:146-150.
9. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T. The need for speed: An update on methamphetamine addiction. J Psychiatry Neurosci. 2006;31:301-113.
10. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O'Dell LE, Parsons LH, Sanna PP. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27:739-749.
11. Koob GF. Neuroadaptive mechanisms of addiction: Studies on the extended amygdala. Eur Neuropsychopharmacol. 2003;13:442-452.
12. Koob GF. Neurobiology of addiction. Toward the development of new therapies. Ann NY Acad Sci. 2000;909:170-185.
13. Koob GF. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann NY Acad Sci. 1999;877:445-460.
14. Weiss F, Koob GF. Drug addiction: Functional neurotoxicity of the brain reward systems. Neurotox Res. 2001;3:145-156.
15. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci. 2001;937:1-26.
16. Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users. Drug Alcohol Rev. 2002;21:179-85.
17. Curtis EK. Meth mouth: A review of methamphetamine abuse and its oral manifestations. Gen Dent. 2006;54:125-129.
18. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J Neuropsychiatry Clin Neurosci. 2003;15:317-325.
19. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: Research findings and clinical directions. J Subst Abuse Treat. 2003;24:267-277.
20. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39:32-41.
21. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murray RM. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33:1407-1414.
22. Harris D, Batki SL. Stimulant psychosis: Symptom profile and acute clinical course. Am J Addict. 2000;9:28-37.
23. Boles SM, Miotto K. Substance abuse and violence: A review of the literature. Aggr Viol Behav, 2003;8:155-174.
24. Sommers I, Baskin D. Methamphetamine use and violence. J Drug Issues, 2006;36:77-96.
25. Cartier J, Farabee D, Prendergast ML. Methamphetamine use, self-reported violent crime, and recidivism among offenders in California who abuse substances. J Interpers Viol. 2006;21:435-445.
26. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust NZ J Psychiatry. 1999;33:89-93.
27. Dyer KR, Cruickshank CC. Depression and other psychological health problems among methamphetamine dependent patients in treatment: Implications for assessment and treatment outcomes. Aust Psychologist, 2003;40:96-108.
28. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: Preliminary findings. Am J Addict. 2004;13:248-255.
29. London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J, Thompson PM, Brody AL, Geaga JA, Hong MS, Hayashi KM, Rawson RA, Ling W. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry. 2005;58:770-778.
30. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23:113-126.
31. Bae SC, Lyoo IK, Sung YH, Yoo J, Chung A, Yoon SJ, Kim DJ, Hwang J, Kim SJ, Renshaw PF. Increased white matter hyperintensities in male methamphetamine abusers. Drug Alcohol Depend. 2006;81:83-88.
32. Kalechstein AD, Newton TF, Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003;15:215-220.
33. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73-84.
34. Simon SL, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat. 2004;27:59-66.
35. Chang L, Smith LM, LoPresti C, Yonekura ML, Kuo J, Walot I, Ernst T. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res. 2004;132:95-106.
36. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology. 2000;54:1344-1349.
37. Woods SP, Rippeth JD, Conover E, Gongvatana A, Gonzalez R, Carey CL, Cherner M, Heaton RK, Grant I. HIV Neurobehavioral Research Center Group: Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology. 2005;19:35-43.
38. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63:90-100.
39. Popova NK. From genes to aggressive behavior: The role of serotonergic system. Bioessays 2006;28:495-503.
40. Badawy AA. Alcohol and violence and the possible role of serotonin. Crim Behav Mental Health. 2003;13:31-44.
41. Krakowski M: Violence and serotonin: Influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003;15:294-305.
42. de Almeida RM, Ferrari PF, Parmigiani S, Miczek KA. Escalated aggressive behavior: Dopamine, serotonin, and GABA. Eur J Pharmacol. 2005;526:51-64.
43. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206-1214.
44. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377-382.
45. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002;26:53-63.
46. Nordahl TE, Salo R, Natsuaki Y, Galloway GP, Waters C, Moore CD, Kile S, Buonocore MH. Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2005; 62:444-452.
47. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161:242-248.
48. Jacobs W. Fatal amphetamine-associated cardiotoxicity and its medicolegal implications. Am J Forensic Med Pathol. 2006;27:156-160.
49. Colfax G, Shoptaw S. The methamphetamine epidemic: Implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2:194-199.
50. Schuckit MA. The treatment of stimulant dependence. Addiction. 1994;89:1559-1563.
51. Lyness WH, Friedle NM, Moore KE. Increased self-administration of d-amphetamine after destruction of 5-hydroxytryptaminergic neurons. Pharmacol Biochem Behav. 1980;12:937-941.
52. Shoptaw S, Huber A, Peck J, Yang X, Liu J, Dang J, Roll J, Shapiro B, Rotheram-Fuller E, Ling W. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:12-18.
53. Piasecki MP, Steinagel GM, Thienhaus OJ, Kohlenberg BS. An exploratory study: The use of paroxetine for methamphetamine craving. J Psychoactive Drugs. 2002;34:301-304.
54. Batki SL, Moon J, Delucchi K, Bradley M, Hersh D, Smolar S, Mengis M, Lefkowitz E, Sexe D, Morello L, Everhart T, Jones RT, Jacob P III. Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann NY Acad Sci. 2000;909:260-263.
55. Batki SL, Moon J, Bradley M, Hersh D, Smolar S, Mengis M, Delucchi K, Sexe D, Bennett S, Lefkowitz E, Chu W, Morello L, Jacob P, Jones RT. Fluoxetine in methamphetamine dependence - a controlled trial: Preliminary analysis. NIDA Research Monograph, Number 180 [Printed in 2000b]. Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting The College on Problems of Drug Dependence, Inc.
56. Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat. 1996;13:493-497.
57. Berigan TR, Russell ML. Treatment of methamphetamine cravings with bupropion: A case report. Prim Care Companion J Clin Psychiatry. 2001;3:267-268.
58. Newton TF, Roache JD, De La Garza R II, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology. 2006;31:1537-1544.
59. Laqueille X, Dervaux A, El Omari F, Kanit M, Bayle FJ. Methylphenidate effective in treating amphetamine abusers with no other psychiatric disorder. Eur Psychiatry. 2005;20:456-457.
60. Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: A placebo-controlled pilot study. Int Clin Psychopharmacol. 2005;20:253-256.
61. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002;68:23-33.
62. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci. 2004;29:452-457.
63. Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, Ling W. Randomized placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006;85:177-184.
64. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005;55:122-125.
65. Fechtner RD, Khouri AS, Figueroa E, Ramirez M, Federico M, Dewey SL, Brodie JD. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: Ocular safety pilot results. Arch Ophthalmol. 2006;124:1257-1262.
66. Johnson BA, Wells LT, Roache JD, Wallace CL, Ait-Daoud N, Dawes MA, Liu L, Wang XQ, Javors MA. Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:455-461.
67. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol. 2007;10:85-98.
68. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of topiramate on methamphetamine-induced changes in attentional and perceptual motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:123-130.
69. Shearer J, Gowing LR. Pharmacotherapies for problematic psychostimulant use: A review of current research. Drug Alcohol Rev. 2004;23:203-211.
70. Rawson RA, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, Ling W. Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis. 2002;21:107-119.
71. Information on Clinical Trials and Human Research Studies. Available at http://www.clinicaltrials.gov/. Accessed July 10, 2007.
72. Freese TE, Obert J, Dickow A, Cohen J, Lord RH. Methamphetamine abuse: Issues for special populations. J Psychoactive Drugs 2000;32:177-182.
73. Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E, Larkins S, Veniegas RC, Freese TE, Hucks-Ortiz C. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78:125-134.
74. Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen A, Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC, Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE, Macdonald M, Liebert M, Rader L, Burns R, DiMaria J, Copersino M, Stabile PQ, Kolodner K, Li R. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A national drug abuse treatment clinical trials network study. Arch Gen Psychiatry. 2005;62:1148-1156.
75. Roll JM, Petry NM, Stitzer ML, Brecht ML, Peirce JM, McCann MJ, Blaine J, MacDonald M, DiMaria J, Lucero L, Kellogg S. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry. 2006;163:1993-1999.
76. Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J. Methamphetamine Treatment Project Corporate Authors: A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708-717.
77. Feeney GFX, Connor JP, Young R, Tucker J, McPherson A. Improvement in measures of psychological distress amongst amphetamine misusers treated with brief cognitive-behavioral therapy (CBT). Addict Behav. 2005;31:1833-1843.